Muscle Characteristics Obtained Using Computed Tomography as Prognosticators in Patients with Castration-Resistant Prostate Cancer by 나군호 et al.
cancers
Article
Muscle Characteristics Obtained Using Computed
Tomography as Prognosticators in Patients with
Castration-Resistant Prostate Cancer
Jongsoo Lee 1 , Jee Soo Park 1 , Ji Eun Heo 1 , Hyun Kyu Ahn 2, Won Sik Jang 1 ,
Won Sik Ham 1 , Koon Ho Rha 1 and Young Deuk Choi 1,*
1 Department of Urology, Urological Science Institute, Yonsei University College of Medicine, 50-1, Yonsei-ro,
Seodaemun-gu, Seoul 03722, Korea; js1129@yuhs.ac (J.L.); sampark@yuhs.ac (J.S.P.); heoji87@yuhs.ac (J.E.H.);
sindakjang@yuhs.ac (W.S.J.); uroham@yuhs.ac (W.S.H.); khrha@yuhs.ac (K.H.R.)
2 Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, 211, Eonju-ro,
Gangnam-gu, Seoul 06273, Korea; wharang11co@yuhs.ac
* Correspondence: youngd74@yuhs.ac; Tel.: +82-2-2228-2310
Received: 11 June 2020; Accepted: 8 July 2020; Published: 10 July 2020


Abstract: Limited studies have investigated the correlation between body composition and prostate
cancer outcomes. We analyzed the effect of muscle mass and quality on castration-resistant prostate
cancer (CRPC) outcomes. Skeletal muscle index (SMI) and skeletal muscle attenuation (SMA) were
measured for 411 patients at the L3 vertebral level using computed tomography at CRPC diagnosis
and were dived to low and high groups at the value of median. Analysis of the skeletal phenotypes
and age (<70 and >70 years) was performed to evaluate the effect of SMI and SMA. The median
survival rates for patients with low and high SMI were 19 and 24 months (p = 0.015), and those with
low and high SMAs were 15 and 26 months (p < 0.001), respectively. In the subgroup analysis by age,
SMA was a significant prognosticator in both groups, while SMI was a significant prognosticator
only in patients aged >70 years. Patients with low SMA + low SMI had the worst prognosis. Muscle
characteristics seems to be a prognosticator in survival of CRPC patients and may be considered in
treatment planning.
Keywords: castration-resistant prostate cancer; body composition; computed tomography;
survival; prognosticator
1. Introduction
Recently, the incidence and prevalence of prostate cancer has increased because of various reasons [1].
However, owing to the development of multimodal treatment and advancements in techniques, survival
rates have increased [2]. Although some drugs are prescribed at a fixed dose for patients receiving
chemotherapy, the dose is often determined based on the body surface area (BSA). However, due to cachexia,
sarcopenia, and obesity, varying toxicities and effectiveness are observed among patients with similar BSA
ranges. Therefore, various researchers have concluded that the BSA should not be the main factor for
dose determination. Many studies were conducted to analyze the association between individual body
composition (including muscle and fat mass) and survival rates using various measurement techniques.
Notably, the relationship between survival rate and muscle characteristics, sarcopenia and myosteatosis, is a
prominent issue for patients with cancer [3]. The degree of sarcopenia and myosteatosis can also be used for
better understanding of a patient’s general health status and individualized management. Sarcopenia is
defined based on the muscle mass of the entire body, which can be represented by several methods such as
dual-energy X-ray absorptiometry, bioelectrical impedance analysis, and muscle indexes calculated from
computed tomography (CT) scan. Among those, muscle area measurement at the L3 level by computed
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tomography is the most widely used method to calculate skeletal muscle index (SMI) or psoas muscle index
(PMI). Using this information, studies have attempted to identify patients with cancer cachexia who cannot
benefit from multimodal treatment and are more suited for palliative therapy [3]. Myosteatosis, an indicator
of muscle quality, can be defined based on the Hounsfield unit (HU) of muscles, which can be represented as
skeletal muscle attenuation (SMA). SMA reflects fat disposition in the muscle tissue which becomes a more
detailed expression of the muscle. Even with similar muscle mass among patients, low SMA represents
lower muscle quality and poor prognosis for elderly patients [4–6]. Because of the development of computer
technology, research on automation of body composition measurements using computed tomography (CT)
is ongoing, with highly accurate results [7,8].
Studies investigating the correlation between body composition and prostate cancer are in progress
but not yielding clear conclusions or consensus. Although studies have attempted to understand
the impact of SMI or PMI on prognosis in patients with castration-naïve and castration-resistant
prostate cancer (CRPC), these are few in number and have reported conflicting results. Furthermore,
there are no reports on the effects of myosteatosis, which is represented as SMA in our study, on CRPC
outcomes. Patients with CRPC are subjected to multimodal medical treatment and prolonged exposure
to androgen deprivation therapy (ADT), which leads to changes in body composition as decrease of
SMI and SMA [9,10]. Considering the characteristics of patients with CRPC, their body composition
and prognosis must be investigated. Therefore, in this study, we aimed to evaluate the relationship
between muscle mass, quality, and survival of these patients. Our study is the first large scaled study
to reveal the significance of both sarcopenia and myosteatosis for survival of patients with CRPC
2. Results
2.1. Patient Characteristics
In total, 411 patients were included in the final analysis. For subgroup analysis, patients were
stratified into two age groups, according to the median age of 70 years at CRPC diagnosis, and into
four groups based on their skeletal muscle phenotype.
The median patient ages at prostate cancer and CRPC diagnosis were 67 (62–72) years and 70
(65–76) years, respectively. The median values of the body mass index (BMI) and BSA were 24.4
(22.5–26.3) kg/m2 and 1.73 (1.64–1.84) m2, respectively. According to the BMI cut-off points proposed
by the World Health Organization for the Asian populations, 52% of the patients were overweight and
9% were obese in our cohort. At the time of CRPC diagnosis, the patients had metastatic lesions in the
bones, lymph nodes, and visceral organs, which occurred in 84%, 47%, and 17% of patients, respectively.
The median prostate-specific antigen (PSA) level at CRPC diagnosis was 44.2 (12.8–158.0) ng/mL. The 1-,
2- and 3-year survival rates from the time since CRPC diagnosis were 68%, 37%, and 24%, respectively.
2.2. Muscle Measurements
The median SMI and SMA values in our cohort were 45.2 (40.6–50.0) cm2/m2 and 32.4 (28.5–36.5)
HU, respectively. When comparing the clinicopathological characteristics, both the high and low SMI
and SMA groups showed significant differences in terms of age; levels of hemoglobin (Hb), alkaline
phosphatase (ALP), and albumin; visceral metastasis at CRPC diagnosis, 1- and 2-year overall survival
rates since CRPC diagnosis; and treated docetaxel cycles. The intermuscular fat area (cm2), Charlson
comorbidity index (CCI), PSA level at CRPC diagnosis, period of ADT administration before CRPC
diagnosis, clinical trial enrollment, and three-year survival since CRPC diagnosis showed significant
differences only between the low and high SMA groups. In contrast, only BMI > 23 kg/m2 and BSA
showed significant differences between the high and low SMI groups (Table 1).
Based on the median SMI and SMA, survival curves were plotted using Cox regression analysis
for the low and high SMI and SMA groups. The median survival rates for the low and high SMI
groups were 19 and 24 months, respectively, and those for the low and high SMA groups were 15 and
26 months, respectively (p = 0.017 and p < 0.001, respectively; Figures 1 and 2).
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Table 1. Clinicopathological characteristics of patients with castration-resistant prostate cancer.
Variables Total(n = 411)
Low SMA
(<32.4 HU) (n = 206)
High SMA
(≥32.4 HU) (n = 205) p-Value
Low SMI
(<45.2 cm2/m2) (n = 207)
High SMI
(≥45.2 cm2/m2) (n = 204) p-Value
Age at CRPC diagnosis, years (IQR) 70 (65–76) 72 (67–77) 69 (63–73) <0.001 72 (67–77) 68 (62–74) <0.001
BMI > 23 kg/m2 (%) 250 117 (57) 133 (65) 0.106 88 (43) 162 (79) <0.001
BSA, m2 (IQR) 1.73 (1.64–1.83) 1.72 (1.63–1.83) 1.74 (1.66–1.85) 0.137 1.7 (1.60–1.79) 1.77 (1.68–1.90) <0.001
Intermuscular area, cm2 (IQR) 6.11 (4.14–8.31) 7.40 (5.30–9.51) 4.89 (3.57–6.90) <0.001 6.21 (4.26–8.78) 6.06 (4.08–7.87) 0.328
Age inclusive CCI > 3 (%) 271 122 (59) 149 (73) 0.005 127 (61) 144 (71) 0.061
KPS > 70 (%) 370 183 (92) 187 (94) 0.441 185 (89) 185 (91) 0.701
PSA at CRPC diagnosis, ng/mL (IQR) 44.2 (12.5–159.1) 63.5 (14.3–175) 31.3 (10.8–110) 0.006 48.5 (12.4–184) 39.1 (12.3–127) 0.109
Hb at CRPC diagnosis (IQR) 12.4 (11.0–13.4) 11.9 (10.8–13.1) 12.7 (11.3–13.6) <0.001 11.9 (10.8–13.2) 12.5 (11.3–13.4) 0.009
ALP at CRPC diagnosis (IQR) 93.0 (69.0–151.0) 108 (75–194) 86 (65–140) 0.004 103 (72–202) 89 (66–138) 0.019
Albumin at CRPC diagnosis (IQR) 4.2 (3.9–4.5) 4.1 (3.8–4.4) 4.3 (4.1–4.6) <0.001 4.1 (3.9–4.4) 4.3 (4.0–4.6) 0.001
Initial treatment (%) 0.055 0.122
Prostatectomy 129 (31) 73 (35) 56 (27) 64 (31) 65 (32)
Radiotherapy 13 (3) 9 (4) 4 (2) 3 (1) 10 (5)
Hormonal therapy 269 (65) 124 (60) 145 (71) 140 (68) 129 (63)
HSPC ADT period, months (IQR) 88 (4–168) 18 (12–39) 27 (15–43) 0.004 21 (12–39) 24 (14–45) 0.109
Docetaxel cycle (IQR) 3 (5–9) 3 (2–7) 6 (3–12) <0.001 4 (2–7) 6 (3–11) <0.001
Metastasis (%)
Bone 344 173 (84) 171 (83) 0.895 179 (87) 165 (81) 0.142
Lymph node 199 104 (51) 95 (45) 0.278 90 (44) 106 (52) 0.094
Visceral 70 46 (22) 24 (12) 0.006 43 (21) 27 (13) 0.049
Overall survival (%)
1 year 257 107 (55) 150 (81) <0.001 116 (61) 141 (75) 0.004
2 year 127 51 (29) 76 (47) 0.001 53 (39) 74 (45) 0.005
3 year 78 33 (19) 45 (30) 0.027 33 (20) 45 (29) 0.07
Clinical trial (%) 84 33 (16) 51 (25) 0.028 43 (21) 41 (20) 0.903
Chi-square test for categorical data and Mann—Whitney U test for continuous data. Values in bold indicate statistically significant data (p < 0.05). SMA, skeletal muscle attenuation; SMI,
skeletal muscle index; CRPC, castration-resistant prostate cancer; BMI, body mass index; BSA, body surface area; CCI, Charlson comorbidity index; KPS, Karnofsky performance score;
PSA, prostate-specific antigen; Hb, hemoglobin; alkaline phosphatase; HSPC, hormone-sensitive prostate cancer; ADT, androgen deprivation therapy; IQR, interquartile range.
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Our subgroup analysis was performed based on the median age at CRPC diagnosis (70 years).
A survival curve was plotted based on the low and high SMA and SMI groups for each age group.
For SMI, a significant difference was found between the low and high groups (17 vs. 29 months) in the
>70-year-old age group (p = 0.002) (Figure 3). For SMA, both the <70- and >70-year-old age groups
showed significant differences in survival [16 (low) vs. 24 months (high) and 14 (low) vs. 30 months
(high); p = 0.005 and 0.027, respectively; Figure 4]. Among the four skeletal muscle phenotypes, the low
SMA + low SMI group had the worst outcome, with statistical significance, compared with the other
three groups. Between low SMA + low SMI and low SMA + high SMI groups, the latter group showed
significantly longer overall survival. (p = 0.013, Figure 5).
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Figure 3. Survival plot based on Cox regression analysis of castration-resistant prostate cancer (CRPC)
survival according to the median skeletal muscle index (SMI; cm2/m2) for the age groups (a) <70 and
(b) >70 years at CRPC diagnosis.
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Figure 4. Survival curves based on Cox regression analysis of the survival of patients with
castration-resistant prostate cancer (CRPC) stratified according to their median skeletal muscle
attenuation (SMA; Hounsfield unit) for the age groups (a) <70 and (b) >70 years at CRPC diagnosis.
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composition and survival of patients with prostate cancer [13–16]. However, muscle mass and prostate
cancer survival did not appear to be correlated. Pak et al. reported a significant relationship between
the PMI and prostate cancer prognosis in an Asian cohort [14]. Although a cut-off value had been
used to define sarcopenia previously, Pak et al. reported differences in prognosis by dividing the PMI
into quartiles.
Patients with CRPC are usually elderly men who have received long-term ADT. Castration through
ADT increases fat mass and decreases muscle mass and quality [17–19]. Smith et al. reported that more
severe sarcopenia developed in older and longer-term recipients of ADT [16]. Chang et al. also reported
that the HU measured before and after ADT (using CT) showed reduced muscle attenuation [20].
These reports suggest that patients with CRPC are more vulnerable to decreased muscle mass and
quality than those with other terminal cancers, owing to the long-term use of ADT.
Although several previous studies have investigated the correlation of patient survival with
sarcopenia and myosteatosis, their definitions varied depending on the type of disease or race [5,21–23].
Moreover, the findings of body composition studies are difficult to apply to patients of different races
and with different diseases [24]. Therefore, the cut-off values used in other studies cannot be applied
to our analysis, and we chose to analyze the trend by applying the median value for each group.
Large-scale studies should be performed with subgrouping of patients by disease, race, and age to
permit the use of body composition values in clinical practice for precise disease management.
There were significant differences in the clinical characteristics of both groups when stratified
according to the median SMA or SMI values. In factors with weight components (such as BMI and
BSA), significant differences were only noted between the low and high SMI groups. Variables that
appeared to be more associated with the survival rate, such as intermuscular fat area, CCI, PSA level
at CRPC diagnosis, and period of ADT administration before CRPC diagnosis, showed significant
differences only between the low and high SMA groups. The intermuscular fat area, rate of visceral
metastasis, period of ADT administration for hormone-sensitive prostate cancer (HSPC), as well as
PSA and ALP levels at CRPC diagnosis were found to be higher in the low SMA group than in the
high SMA group. Although there is no clear mechanism to explain this phenomenon, it is possible that
the patients in the low SMA group received shorter periods ADT for HSPC because of early disease
progression with higher rates of visceral metastasis, with consequently higher PSA and ALP levels.
Focusing on the treated cycles of docetaxel, significantly higher numbers of cycles were treated in the
high SMA and SMI groups. This finding is consistent with those of a previous study that reported
sarcopenia as a poor prognostic factor for docetaxel-treated patients with CRPC [25]. These results
suggest that the SMI and SMA constitute a comprehensive representation of several biological factors
that could predict patient survival; SMA appears to be a more valuable prognosticator for patients
with CRPC. It is plausible that although the muscle mass decreases in patients with CRPC who have
undergone ADT, more attention needs to be given to increased intramyocellular fat. In our cohort,
intermuscular fat area was significantly higher in the low SMA group, possibly indicating that the
amount of intramyocellular fat correlated with the intermuscular fat area, whereas the SMI groups
did not show significant differences. Moreover, in our cohort, the high SMA group demonstrated a
significantly higher proportion of clinical trial enrollment than the low SMA group, whereas the SMI
groups did not show any significant differences. However, among the low SMA group, as high SMI
showed to have significantly longer survival, SMI also seems to be a meaningful factor for prediction
of survival (Figure 5). Furthermore, the effects of clinical trial enrollment on survival have previously
been reported in patients with CRPC [26]. Because there are several studies on the prognosis of patients
with cancer and intermuscular fat area, a comprehensive study should be conducted, and cut-off values
should be defined according to the patients’ BMI.
Previous studies have reported conflicting results for the relationship between the SMI or PMI
and the prognosis of prostate cancer among patients belonging to different ethnicities [24,25]. Various
conclusions have been made depending on the type of disease or criteria used to define sarcopenia
and myosteatosis [27]. For patients with prostate cancer, the use of ADT may result in increased
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intramuscular fat accumulation. Although muscle mass appeared to be maintained (i.e., minimal
change was observed in the SMI), the muscle quality decreased (i.e., a marked change was observed in
muscle attenuation), which possibly explains the increased intramuscular fat accumulation. In our
cohort, SMI showed a significant difference in the results of univariate Cox regression analysis but
not in those of the multivariate Cox regression analysis (Table 2). After subgrouping the cohort
according to the median age at CRPC diagnosis (<70 or >70 years), we found that a high SMI was an
important prognosticator for patients aged >70 years. Between the Asian and non-Asian populations,
muscle mass was a survival prognosticator in relatively leaner and older patients. Furthermore,
age was not a statistically significant prognosticator for survival based on the result of univariate
or multivariate Cox regression analyses (hazard ratio [HR], 1.01; confidence interval [CI], 0.99–1.02;
p = 0.53). The results of both univariate and multivariate Cox regression analyses showed that SMA
was a statistically significant prognosticator for survival (low vs. high, 15 vs. 26 months, p <0.001;
HR, 0.70; CI, 0.55–0.90; p = 0.005). After subgrouping according to the median age of 70 years, SMA
was a significant prognosticator in both groups based on Cox regression analysis (<70 years: 16 vs.
24 months, p = 0.004; >70 years: 14 vs. 30 months, p = 0.02, respectively). These findings suggest that
for patients aged >70 years, the functional age, which can be represented by the muscle mass, is a more
influential prognosticator than the chronological age.
Table 2. Results of Cox regression analysis for patients with castration-resistant prostate cancer.
Variables
Univariate Multivariate a
HR CI p-Value HR CI p-Value
Age at CRPC diagnosis 1.01 (0.99–1.02) 0.526
BMI (<23 vs. ≥23 kg/m2) 0.60 (0.48–0.76) <0.001 0.85 (0.62–1.17) 0.329
BSA for every 0.2 increase 0.71 (0.61–0.83) <0.001 0.83 (0.67–1.03) 0.084
Age inclusive CCI (<4 vs. ≥4) 1.04 (0.81–1.33) 0.777
KPS (≥70 vs. <70) 1.85 (1.24–2.78) 0.003 0.89 (0.54–1.46) 0.649
PSA at CRPC diagnosis for every 1.0 increase 1.00 (1.00–1.00) <0.001 1.00 (1.00–1.00) <0.001
Hb at CRPC diagnosis for every 1.0 increase 0.77 (0.72–0.82) <0.001 0.88 (0.81–0.95) 0.002
ALP at CRPC diagnosis for every 1.0 increase 1.00 (1.00–1.00) <0.001 1.00 (1.00–1.00) <0.001
Albumin at CRPC diagnosis for every 1.0 increase 0.49 (0.38–0.63) <0.001 1.02 (0.73–1.44) 0.899
Bone metastasis (no vs. yes) 1.88 (1.30–2.72) 0.001 1.55 (1.04–2.32) 0.03
Lymph node metastasis (no vs. yes) 1.43 (1.14–1.81) 0.002 1.56 (1.20–2.01) 0.001
Visceral metastasis (no vs. yes) 2.35 (1.77–3.13) <0.001 2.00 (1.47–2.73) <0.001
SMI (low vs. high) 0.75 (0.60–0.95) 0.017 1.01 (0.78–1.32) 0.92
SMA (low vs. high) 0.65 (0.52–0.83) <0.001 0.70 (0.55–0.90) 0.005
a Significant variables from the univariate analysis were included in the multivariate model. Values in bold indicate
statistically significant data (p < 0.05); HR, hazard ratio; CI, confidence interval; SMA, skeletal muscle attenuation;
SMI, skeletal muscle index; CRPC, castration-resistant prostate cancer; BMI, body mass index; BSA, body surface
area; CCI, Charlson comorbidity index; KPS, Karnofsky performance score; PSA, prostate-specific antigen; Hb,
hemoglobin; ALP, alkaline phosphatase; IQR, interquartile range.
The recent development of various anticancer drugs has led to increased survival. However,
with increased survival time and the prolonged use of anticancer drugs, increased muscle degeneration
and intramuscular fat accumulation may occur, leading to sarcopenia and myosteatosis. As a result,
the metabolism and detoxification rates of drugs decrease, resulting in the increased occurrences
of side-effects and decline in general health [25]. These findings suggest that analyzing muscle
characteristics at the time of CRPC diagnosis can help to predict CRPC prognosis. The results of the
present study suggest that the SMA for patients of all ages and the SMI for those aged >70 years
were more meaningful prognosticators than age itself. Moreover, the analysis of the skeletal muscle
phenotype revealed that the low SMA + low SMI group had the worst outcome. These findings
may aid physicians in the identification of patients who require definitive treatment or conservative
management. Functional age can be considered to play a role in the decrease in physical function,
which was previously difficult to measure objectively. The conventional method for determining the
optimal, patient-specific drug dose using BSA is subject to changes; these variations are caused by
variations in the measurement of body composition using various diagnostic devices. In the current
era of precision medicine, the use of body composition parameters such as SMI and SMA may be
advantageous to accurately identify patient status and may lead to better treatment decisions, especially
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when treating patients of varying ages and races with different carcinomas. With the development
of computer science, time-consuming and arduous measurement of the body composition may be
automated in the near future [7,8].
There are several limitations in this study. First, because of its retrospective design, a selection
bias may be present and the research methodology itself may be a limitation. Second, not all patients
received the same treatment because treatments were determined by the treating physician and were
based on a patient’s disease characteristics. Third, because of differences in the ethnicity and diseases
of the patients, the cut-off values used in this study should not be considered the gold-standard value
for other studies. Fourth, the analysis was done only by the data at CRPC diagnosis, where comparing
the differences of SMA and SMI before and after ADT may support our findings. Fifth, the image
analysis program used in our study may not be available at every center; this may be considered as a
technical limitation.
Despite these limitations, this study provides meaningful results because a large cohort of
>400 patients with CRPC was included. Furthermore, this was the first study to identify SMA as
a prognosticator for the survival of patients with CRPC and to evaluate its correlation with other
clinical variables.
4. Materials and Methods
4.1. Study Population
This was a single-center cohort study in which patients were treated by different urologists.
The study was approved by the institutional review board of Yonsei University College of Medicine.
(IRB 2020-1413-001) We reviewed the electronic medical records of 453 consecutive patients with
prostate cancer who progressed to CRPC between March 2005 and May 2019. The patients were
excluded from the analysis if they did not have an appropriate pre-contrast CT image (n = 23), were lost
to follow-up (n = 9), or had an unknown cause of death (n = 10).
The diagnosis of prostate cancer was established based on the results of pathological examination
of trans-rectal or trans-perineal prostate biopsy specimens. Additional pathological examinations for
staging were performed for the patients who underwent radical prostatectomy. The clinical cancer
stage was determined according to the 8th version of the American Joint Committee on Cancer Tumor
Node Metastasis system. CRPC was defined as disease progression confirmed by over two consecutive
continuous increases in the serum PSA level or the appearance of new metastases detected on imaging,
despite the administration of ADT and castrate levels of testosterone (≤50 ng/mL).
Treatments for patients with CRPC were determined at the physician’s discretion after full
discussion with the patient. The treatment agents used included abiraterone, enzalutamide, cabazitaxel,
and docetaxel. Each regimen was continued until the patient experienced intolerable side-effects
or disease progression or until they refused further treatment. Serum PSA measurements were
performed every 1–3 months, and CT, magnetic resonance imaging, or bone scans were performed
every 2–6 months at the physician’s discretion.
4.2. Anthropometric and Muscle Characteristic Assessment
Height (m) and weight (kg) were measured when determining the amount of contrast agent
to be administered for imaging. The BMI was categorized using the World Health Organization
Classifications for Asian populations [28]. The BSA was calculated using the Mosteller formula [29].
The muscle characteristic parameters were obtained using CT findings at the time of CRPC
diagnosis. With the pre-contrast CT image, the muscle and intermuscular fat areas on a single
cross-sectional image at the level of the L3 vertebra were analyzed using a technique that was
previously shown to have high correlation with the total-body skeletal muscle (R2 = 0.86) [12].
The areas with different body compositions were automatically outlined using specific HU ranges,
from −29 to +150 for the muscle and from −200 to −50 for the intermuscular fat area, according to
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previous studies, and the outline was manually adjusted, if required [30]. An image analysis program
was used for measurement of the CT images (Aquarius Intuition Viewer version 4.4.12; TeraRecon, CA,
USA). The muscle characteristics were categorized as SMI (cm2/m2) and SMA (HU).
4.3. Cut-Off Values for Dichotomization
Considering the lack of international or regional consensus on sarcopenia or myosteatosis
(according to the CT values), we divided the patients according to their median SMI and SMA values
into low and high SMI and SMA groups. The skeletal muscle phenotype was determined based on the
following combinations of the SMI and SMA values: high SMA + high SMI, high SMA + low SMI,
low SMA + high SMI, and low SMA + low SMI [31].
4.4. Study Endpoints
The primary endpoint of our study was the correlation between survival and muscle characteristics
(SMI and SMA) obtained using CT images. The secondary endpoint was the correlation between muscle
characteristics and survival within the groups stratified by age and by skeletal muscle phenotype.
4.5. Statistical Analysis
Mann–Whitney U-tests were performed for descriptive variables [32]. The Fisher’s exact test
was performed to compare the categorical variables. Survival analyses were performed using Cox
regression analyses. SMI and SMA were dichotomized by their median values and referred to as
low and high SMI and SMA, respectively. Statistical analyses were performed using SPSS (SPSS for
Windows, version 25.0, IBM, Chicago, IL, USA). p-values < 0.05 were considered statistically significant.
5. Conclusions
SMI and SMA values can predict the prognosis of metastatic CRPC. In the era of advanced
imaging techniques and computer science, the SMI and SMA may soon replace the BMI and BSA.
The former may become determinants for treatment choices in the future. As unfavorable skeletal
muscle phenotypes can lead to worse patient outcomes, detailed investigations are required in this
area. Large-scale studies involving patients of different ethnicities, diseases, and ages are needed to
further understand the criteria for selecting optimal treatment.
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